Surgical Endoscopy

, Volume 30, Issue 8, pp 3289–3296 | Cite as

Multi-institutional outcomes using magnetic sphincter augmentation versus Nissen fundoplication for chronic gastroesophageal reflux disease

  • Heather F. Warren
  • Jessica L. Reynolds
  • John C. Lipham
  • Joerg Zehetner
  • Nikolai A. Bildzukewicz
  • Paul A. Taiganides
  • Jody Mickley
  • Ralph W. Aye
  • Alexander S. Farivar
  • Brian E. Louie
Article

Abstract

Background

Magnetic sphincter augmentation (MSA) has emerged as an alternative surgical treatment of gastroesophageal reflux disease (GERD). The safety and efficacy of MSA has been previously demonstrated, although adequate comparison to Nissen fundoplication (NF) is lacking, and required to validate the role of MSA in GERD management.

Methods

A multi-institutional retrospective cohort study of patients with GERD undergoing either MSA or NF. Comparisons were made at 1 year for the overall group and for a propensity-matched group.

Results

A total of 415 patients (201 MSA and 214 NF) underwent surgery. The groups were similar in age, gender, and GERD-HRQL scores but significantly different in preoperative obesity (32 vs. 40 %), dysphagia (27 vs. 39 %), DeMeester scores (34 vs. 39), presence of microscopic Barrett’s (18 vs. 31 %) and hiatal hernia (55 vs. 69 %). At a minimum of 1-year follow-up, 354 patients (169 MSA and 185 NF) had significant improvement in GERD-HRQL scores (pre to post: 21–3 and 19–4). MSA patients had greater ability to belch (96 vs. 69 %) and vomit (95 vs. 43 %) with less gas bloat (47 vs. 59 %). Propensity-matched cases showed similar GERD-HRQL scores and the differences in ability to belch or vomit, and gas bloat persisted in favor of MSA. Mild dysphagia was higher for MSA (44 vs. 32 %). Resumption of daily PPIs was higher for MSA (24 vs. 12, p = 0.02) with similar patient-reported satisfaction rates.

Conclusions

MSA for uncomplicated GERD achieves similar improvements in quality of life and symptomatic relief, with fewer side effects, but lower PPI elimination rates when compared to propensity-matched NF cases. In appropriate candidates, MSA is a valid alternative surgical treatment for GERD management.

Keywords

Gastroesophageal reflux disease Anti-reflux surgery Multi-institutional Nissen fundoplication Outcomes 

Notes

Acknowledgments

Dr. Heather Warren’s Advanced Gastrointestinal Surgery Fellowship at Swedish Medical Center was supported in part by the Ryan Hill Foundation.

Compliance with ethical standards

Disclosures

Drs. Lipham, Taiganides and Louie have received consulting fees from Torax Medical. Drs. Warren, Reynolds, Zehetner, Bildzukewicz, Aye, and Farivar, and Ms. Mickley have no conflicts of interest or financial ties to disclose.

References

  1. 1.
    Dent J, El-Serag HB, Wallander MA, Johansson S (2005) Epidemiology of gastroesophageal reflux disease: a systematic review. Gut 54:710–717CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Toghanian S, Johnson DA, Stalhammar NO, Zerbib R (2011) Burden of gastroesophageal reflux disease in patients with persistent and intense symptoms despite proton pump inhibitor therapy; a post hoc analysis of the 2007 National Health and Wellness Survey. Clin Drug Investig 31:703–715CrossRefPubMedGoogle Scholar
  3. 3.
    Ying C (2015) Gastroesophageal reflux disease and non-digestive tract diseases. Expert Rev Gastroenterol Hepatol 9:685–692CrossRefGoogle Scholar
  4. 4.
    Lord RVN, DeMeester SR, Peters JH, Hagen JH, Elyssnia D, Sheth CT, DeMeester TR (2009) Hiatal hernia, lower esophageal sphincter incompetence and effectiveness of Nissen fundoplication in the spectrum of gastroesophageal reflux disease. J Gastrointest Surg 13:602–610CrossRefPubMedGoogle Scholar
  5. 5.
    El-Serag HB (2007) Time trends of gastroesophageal reflux disease: a systematic review. Clin Gastroenterol Hepatol 5:17–26CrossRefPubMedGoogle Scholar
  6. 6.
    Lagergren J, Bergstrom R, Lindgren A, Nyren O (1999) Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. NEJM 340:825–831CrossRefPubMedGoogle Scholar
  7. 7.
    Lundell L, Miettinen P, Myrvold HE, Hatlebakk JG, Wallin L, Engstrom C, Julkunen R, Montgomery M, Malm A, Lind T, Walan A, Nordic GERD Study Group (2009) Comparison of outcomes twelve years after antireflux surgery or omeprazole maintenance therapy for reflux esophagitis. Clin Gastroenterol Hepatol 7:1292–1298CrossRefPubMedGoogle Scholar
  8. 8.
    Galmiche JP, Hatlebakk J, Attwood S, Ell C, Fiocca R, Eklund S, Langstrom G, Lind T, Lundell L (2011) Laparoscopic antireflux surgery vs esomeprazole treatment for chronic GERD: the LOTUS randomized clinical trial. JAMA 305:1969–1977CrossRefPubMedGoogle Scholar
  9. 9.
    Stein HJ, Barlow AP, DeMeester TR, Hinder RA (1992) Complications of gastroesophageal reflux disease. Role of the lower esophageal sphincter, esophageal acid and acid/alkaline exposure, and duodenogastric reflux. Ann Surg 216:35–43CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Finks J, Wei Y, Birkmeyer J (2006) The rise and fall of antireflux surgery in the United States. Surg Endosc 20:1698–1701CrossRefPubMedGoogle Scholar
  11. 11.
    Katz PO, Zavala S (2010) Proton pump inhibitors in the management of GERD. J Gastrointest Surg 14(S1):S62–S66CrossRefPubMedGoogle Scholar
  12. 12.
    Kahrilas P, Jonsson A, Denison H, Wernersson B, Hughes N, Howden C (2012) Regurgitation is less responsive to acid suppression than heartburn in patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol 10:612–619CrossRefPubMedGoogle Scholar
  13. 13.
    Kahrilas PJ (2008) Gastroesophageal reflux disease. NEJM 359:1700–1707CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Castell DO, Kahrilas PJ, Richer JE, Vakil NB, Johnson DA, Zuckerman S, Skammer W, Levine JG (2002) Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 97:575–583CrossRefPubMedGoogle Scholar
  15. 15.
    Tauseef A, David RN, William TM (2009) Long term safety concerns with proton pump inhibitors. Am J Med 122:896–903CrossRefGoogle Scholar
  16. 16.
    Bonavina L, Saino GI, Bona D, Lipham J, Ganz RA, Dunn D, DeMeester T (2008) Magnetic augmentation of the lower esophageal sphincter: results of a feasibility clinical trial. J Gastrointest Surg 12:2133–2140CrossRefPubMedGoogle Scholar
  17. 17.
    Wileman SM, McCann S, Grant AM, Krukowski ZH (2010) Medical versus surgical management for gastro-oesophageal reflux disease (GORD) in adults. Cochrane Database Syst Rev 13:332–341Google Scholar
  18. 18.
    Varban OA, McCoy TP, Westcott C (2011) A comparison of preoperative comorbidities and post operative outcomes among patients undergoing laparoscopic nissen fundoplication at high and low volume centers. J Gastrointest Surg 15:1121–1127CrossRefPubMedGoogle Scholar
  19. 19.
    Peters JH, DeMeester TR, Crookes P, Oberg S, Vos Shoop M, Hagen JA, Bremner CG (1998) The treatment of gastroesophageal reflux disease with laparoscopic Nissen fundoplication. A prospective evaluation of 100 patients with typical symptoms. Ann Surg 228(1):40–50CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Dellemagne B, Weerts J, Markiewics S, Dewandre JM, Wahlen C, Monami B, Jehaes C (2006) Clinical results of laparoscopic fundoplication at ten years after surgery Surg. Endoscopy 20:159–165CrossRefGoogle Scholar
  21. 21.
    Kelly J, Watson D, Chin K, Devitt P, Game P, Jamieson G (2007) Laparoscopic Nissen fundoplication: clinical outcomes at 10 years. J Am Coll Surg 205:570–575CrossRefPubMedGoogle Scholar
  22. 22.
    Morgenthal C, Shane M, Steval A, Gletsu N, Milam G, Milam G, Swafford V, Hunter JG, Smith CD (2007) The durability of laparoscopic Nissen fundoplication: 11 year outcomes. J Gastrointest Surg 11:693–700CrossRefPubMedGoogle Scholar
  23. 23.
    Hunter J, Smith C, Branum G, Waring J, Trus T, Cornwell M, Galloway K (1999) Laparoscopic fundoplication failures: patterns of failure and response to fundoplication. Ann Surg 230:595–606CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Lipham JC, Taiganides PA, Louie BE, Ganz RA, DeMeester TR (2014) Safety analysis of first 1000 patients treated with magnetic sphincter augmentation for gastroesophageal reflux disease. Dis Esophagus. doi: 10.1111/dote.12199 Google Scholar
  25. 25.
    Riegler M, Sebastian FS, Bonavina L, Ashton D, Horbach T, Kemen M (2014) Magnetic sphincter augmentation and fundoplication for GERD in clinical practice: one year results of a multicenter, prospective observational study. Surg Endosc 29(5):1123–1129CrossRefPubMedGoogle Scholar
  26. 26.
    Catarci M, Gentileschi P, Papi C, Carrara A, Marrese R, Gaspari L, Grassi GB (2004) Evidence based appraisal of antireflux fundoplication. Ann Surg 23:325–337CrossRefGoogle Scholar
  27. 27.
    Wang YR, Dempsey DT, Richter JE (2011) Trends and perioperative outcomes in inpatient antireflux surgery in the United States, 1993–2006. Dis Esophagus 24:215–223CrossRefPubMedGoogle Scholar
  28. 28.
    Richter JE (2013) Gastroesophageal reflux disease treatment: side effects and complications of fundoplication. Clin Gastroeneterol Hepatol 11:465–471CrossRefGoogle Scholar
  29. 29.
    Carlson MA, Frantzides CT (2001) Complications and results of primary minimally invasive antireflux procedures: a review of 10735 reported cases. J Am Coll Surg 193:428–439CrossRefPubMedGoogle Scholar
  30. 30.
    Ganz RA, Gostout CJ, Grudem J, Swanson W, Berg T, DeMeester TR (2008) Use of a magnetic sphincter for the treatment of GERD: a feasibility study. Gastrointest Endosc 67(2):287–294CrossRefPubMedGoogle Scholar
  31. 31.
    Ganz RA, Peters JH, Horgan S, Bermelman WA, Dunst CM, Edmondowicz SA, Lipham JC, Lukitich JD, Melvin WS, Oelschlager BK, Schlack-Haerere SC, Smith CD, Smith CC, Dunn D, Taiganides PA (2013) Esophageal sphincter device for gastroesophageal reflux disease. N Engl J Med 368:719–727CrossRefPubMedGoogle Scholar
  32. 32.
    Bonavina L, Saino G, Bona D, Sironi A, Lazzari V (2013) One hundred consecutive patients treated with magnetic sphincter augmentation for gastroesophageal reflux disease: 6 years of clinical experience from a single center. J Am Coll Surg 17:577–585CrossRefGoogle Scholar
  33. 33.
    Bonavina L, DeMeester T, Fockens P, Dunn D, Saino G, Bona D, Lipham J, Bemelman W, Ganz R (2010) Laparoscopic sphincter augmentation device eliminates reflux symptoms and normalizes esophageal acid exposure. One and 2 year results of a feasibility trail. Ann Surg 252(5):857–862CrossRefPubMedGoogle Scholar
  34. 34.
    Lipham JC, DeMeester TR, Ganz RA, Bonavina L, Saino G, Dunn DH, Fockens P, Bemelman W (2012) The LINX reflux management system: confirmed safety and efficacy now at 4 years. Surg Endosc 26:2944–2949CrossRefPubMedGoogle Scholar
  35. 35.
    Louie BE, Farivar AS, Shultz D, Brennan C, Vallieres E, Aye RW (2014) Short term outcomes using magnetic sphincter augmentation versus nissen fundoplication for medically resistant gastroesophageal reflux disease. Ann Thorac Surg 98(2):498–504CrossRefPubMedGoogle Scholar
  36. 36.
    Sheu EG, Nau P, Nath B, Kuo B, Rattner DW (2015) A comparative trial of laparoscopic magnetic sphincter augmentation and nissen fundoplication. Surg Endosc 29:505–509CrossRefPubMedGoogle Scholar
  37. 37.
    Reynolds J, Zehetner J, Wu P, Shah S, Bildzukewicz Lipham J (2015) Laparoscopic magnetic sphincter augmentation versus laparoscopic Nissen fundoplication: a matched pair analysis of 100 patients. J Am Coll Surg 221(1):123–128CrossRefPubMedGoogle Scholar
  38. 38.
    Simorov A, Ranade A, Jones R, Tadaki C, Shostrom V, Boilesen E (2014) Long term patient outcomes after laparoscopic anti reflux procedures. J Gastrointest Surg 18(1):157–162CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Heather F. Warren
    • 1
  • Jessica L. Reynolds
    • 2
  • John C. Lipham
    • 2
  • Joerg Zehetner
    • 2
  • Nikolai A. Bildzukewicz
    • 2
  • Paul A. Taiganides
    • 3
  • Jody Mickley
    • 3
  • Ralph W. Aye
    • 1
  • Alexander S. Farivar
    • 1
  • Brian E. Louie
    • 1
  1. 1.Division of Thoracic SurgerySwedish Medical Center and Cancer InstituteSeattleUSA
  2. 2.Division of Upper GI and General SurgeryKeck Medical Center at University of Southern CaliforniaLos AngelesUSA
  3. 3.Knox Community HospitalMount VernonUSA

Personalised recommendations